HomeCLINICAL TRIALS, STUDIES, REGISTRIES, DATA

CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

Aquedeon Medical Announces First Patient Enrolled in the IDE Study of Duett Vascular Graft System

This February, the first enrolled patient underwent open surgical aortic arch reconstruction at the University of Pennsylvania, Presbyterian Medical Center, Philadelphia, PA.  During the surgery, the Duett Vascular Graft System was successfully deployed to connect the native left common carotid artery to the surgical graft.

Aquedeon Medical Announces First Patient Enrolled in the IDE Study of Duett Vascular Graft System

This February, the first enrolled patient underwent open surgical aortic arch reconstruction at the University of Pennsylvania, Presbyterian Medical Center, Philadelphia, PA.  During the surgery, the Duett Vascular Graft System was successfully deployed to connect the native left common carotid artery to the surgical graft.

Auxilius Pharma Announces Top-line Results of its First-in-Human Clinical Study into the Pharmacokinetics, Safety and Tolerability of Antianginal AUX-001

AUX-001 is an innovative, once-daily, extended-release formulation of Nicorandil. For decades, immediate-release, twice daily Nicorandil has been a cornerstone treatment for chronic angina symptoms outside the US, distinguished by its dual mechanism of action that targets both the micro- and macrovascular coronary artery flow bed, and providing sustained angina symptom relief without the common issue of tachyphylaxis seen with other anti-anginal vasodilators like long-acting nitrates. AUX-001 offers efficacy comparable to conventional anti-anginal medications such as beta-blockers, calcium channel blockers, and long-acting nitrates while also potentially enhancing control of the underlying coronary disease and reducing angina related hospitalizations.

Conformal Medical’s CLAAS® System Demonstrates Low Thrombogenicity Compared to Commercially Available LAAO Devices

Conformal Medical is actively enrolling patients in the CONFORM pivotal trial, evaluating the safety and efficacy of the CLAAS System compared to other commercially available LAAO devices. The prospective, multicenter, randomized controlled study will enroll approximately 1,600 patients.

By using this website you agree to accept Medical Device News Magazine Privacy Policy